Immune check point inhibitors are the class of drugs that fight with immune system of the body to fight cancerous cells. However, most patients do not respond to these therapy. There is a newer class of drug that targets two proteins involved in the suppressing the body’s immune response against tumors.
Phase I of clinical trials have shown some exciting results which were conducted in 19 patients suffering from cancer in with the molecule called M7824. These researchers are also undertaking trials suffering from pancreatic cancer and those infected with HPV.
There are many other trials and experiments being taken to treat and cure cancer more effectively in different research institutes. This drug with dual approach will be a boon in the treatment of cancer as with a single molecule multiple therapies are included.
